Albuminuria: A Great Risk Marker, but an Underestimated Target in Diabetes

被引：11

作者：

de Zeeuw, Dick ^{[1
]}

Raz, Itamar ^{[2
]}

机构：

[1] Univ Groningen, Dept Clin Pharmacol, Univ Med Ctr Groningen, NL-9700 AG Groningen, Netherlands

[2] Hadassah Univ Hosp, Dept Med, Diabet Unit, IL-91240 Jerusalem, Israel

来源：

DIABETES CARE | 2008年 / 31卷

关键词：

D O I：

10.2337/dc08-s248

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：S190 / S193

页数：4

共 27 条

[1] Antiproteinuric effect of oral paricalcitol in chronic kidney disease [J].

Agarwal, R ;

Acharya, M ;

Tian, J ;

Hippensteel, RL ;

Melnick, JZ ;

Qiu, P ;

Williams, L ;

Batlle, D .

KIDNEY INTERNATIONAL, 2005, 68 (06) :2823-2828

[2]

APPERLOO AJ, 1994, KIDNEY INT, V45, pS174

[3] Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy [J].

Atkins, RC ;

Briganti, EM ;

Lewis, JB ;

Hunsicker, LG ;

Braden, G ;

de Crespigny, PJC ;

DeFerrari, G ;

Drury, P ;

Locatelli, F ;

Wiegmann, TB ;

Lewis, EJ .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (02) :281-287

[4] Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy [J].

Bos, H ;

Andersen, S ;

Rossing, P ;

de Zeeuw, D ;

Parving, HH ;

de Jong, PE ;

Navis, G .

KIDNEY INTERNATIONAL, 2000, 57 :S32-S37

[5] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].

Brenner, BM ;

Cooper, ME ;

de Zeeuw, D ;

Keane, WF ;

Mitch, WE ;

Parving, HH ;

Remuzzi, G ;

Snapinn, SM ;

Zhang, ZX ;

Shahinfar, S .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869

[6] The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide [J].

Buter, H ;

Hemmelder, MH ;

Navis, G ;

de Jong, PE ;

de Zeeuw, D .

NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (07) :1682-1685

[7] Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy [J].

de Zeeuw, D ;

Remuzzi, G ;

Parving, HH ;

Keane, WF ;

Zhang, ZX ;

Shahinfar, S ;

Snapinn, S ;

Cooper, ME ;

Mitch, WE ;

Brenner, BM .

CIRCULATION, 2004, 110 (08) :921-927

[8] Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL [J].

de Zeeuw, D ;

Remuzzi, G ;

Parving, HH ;

Keane, WF ;

Zhang, ZX ;

Shahinfar, S ;

Snapinn, S ;

Cooper, MF ;

Mitch, WE ;

Brenner, BM .

KIDNEY INTERNATIONAL, 2004, 65 (06) :2309-2320

[9] Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy:: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial [J].

Eijkelkamp, Wouter B. A. ;

Zhang, Zhongxin ;

Remuzzi, Giuseppe ;

Parving, Hans-Henrik ;

Cooper, Mark E. ;

Keane, William F. ;

Shahinfar, Shahnaz ;

Gleim, Gilbert W. ;

Weir, Matthew R. ;

Brenner, Barry M. ;

de Zeeuw, Dick .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 18 (05) :1540-1546

[10] Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type I and type 2 diabetic patients:: The Di.NAS randomized trial [J].

Gambaro, G ;

Kinalska, I ;

Oksa, A ;

Pontuch, P ;

Hertlová, M ;

Olsovsky, J ;

Manitius, J ;

Fedele, D ;

Czekalski, S ;

Perusicová, J ;

Skrha, J ;

Taton, J ;

Grzeszczak, W ;

Crepaldi, G .

JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (06) :1615-1625

← 1 2 3 →